Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RINGSIDE: AL102 in Patients with Progressing Desmoid Tumors
2020-005833-34Phase 2Active
- Sponsor
- Ayala Pharmaceuticals, Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of varegacestat in aggressive fibromatosis (AF), sponsored by Ayala Pharmaceuticals, Inc. Primary endpoints: Safety and tolerability (TEAEs and SAEs) and Time to treatment discontinuation due to TEAE. Started Jul 2021; status: active.
02
Drugs
varegacestat
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on 2020-005833-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005833-34.